Investigating the effect of local, oral and intravenous tranexamic acid on the amount of bleeding during humerus fracture surgery

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N184

Enrollment

Registered

2023-05-29

Start date

2023-06-05

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Humerus fracture. Age-related osteoporosis with current pathological fracture, humerus

Interventions

Intervention 1: Intervention group 1: patients will receive 20 mg/kg tranexamic acid IV. Intervention 2: Intervention group 2: Patients receive 1 gram of tranexamic acid orally 1 hour before surgery w

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: All patients with ASA class 1 and 2 All patients with humerus fracture All patients candidates for elective surgery 18 to 70 years Patients with BMI greater than 30 Patients candidate for general anesthesia

Exclusion criteria

Exclusion criteria: Pregnancy Underlying kidney, heart, lung, and liver disease Sensitivity to tranexamic acid No consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Bleeding. Timepoint: During the operation, recovery and 24 and 48 hours after the operation. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohsen Parsi Khameneh

Arak University of Medical Sciences

parsi@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026